OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry

Chauvin, M.; Borys, Damian; Botta, Francesca; Bzowski, Paweł; Dabin, Jérémie; Bacelar, A. M. Denis; Desbrée, Aurélie; Falzone, Nadia; Lee, Boon Quan; Mairani, A.; Malaroda, Alessandra; Mathieu, G.; McKay, Erin; Mora‐Ramirez, Erick; Robinson, Andrew; Sarrut, David; Struelens, Lara; Gil, Alberto; Bardiès, Manuel

doi:10.2967/jnumed.119.240366

Cited by 60 publications

(35 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dose estimation is a very important part of quality assurance programs in medical radiology. However, only few validated and freely available programs are currently available for nuclear medicine (6,50). The present study combines, for the first time, a chemical dosimeter and PET imaging to evaluate the radiation dose of the 18 F-FDG PET radiotracer.…”

Section: Discussionmentioning

confidence: 99%

Estimation of the Internal Dose Imparted by 18F-Fluorodeoxyglucose to Tissues by Using Fricke Dosimetry in a Phantom and Positron Emission Tomography

et al. 2022

View full text Add to dashboard Cite

PurposeAssessment of the radiation dose delivered to a tumor and different organs is a major issue when using radiolabelled compounds for diagnostic imaging or endoradiotherapy. The present article reports on a study to correlate the mean 18F-fluorodeoxyglucose (18F-FDG) activity in different tissues measured in a mouse model by positron emission tomography (PET) imaging, with the dose assessed in vitro by Fricke dosimetry.MethodsThe dose-response relationship of the Fricke dosimeter and PET data was determined at different times after adding 18F-FDG (0–80 MBq) to a Fricke solution (1 mM ferrous ammonium sulfate in 0.4 M sulfuric acid). The total dose was assessed at 24 h (~13 half-lives of 18F-FDG). The number of coincident events produced in 3 mL of Fricke solution or 3 mL of deionized water that contained 60 MBq of 18F-FDG was measured using the Triumph/LabPET8TM preclinical PET/CT scanner. The total activity concentration measured by PET was correlated with the calculated dose from the Fricke dosimeter, at any exposure activity of 18F-FDG.ResultsThe radiation dose measured with the Fricke dosimeter increased rapidly during the first 4 h after adding 18F-FDG and then gradually reached a plateau. Presence of non-radioactive-FDG did not alter the Fricke dosimetry. The characteristic responses of the dosimeter and PET imaging clearly exhibit linearity with injected activity of 18F-FDG. The dose (Gy) to time-integrated activity (MBq.h) relationship was measured, yielding a conversion factor of 0.064 ± 0.06 Gy/MBq.h in the present mouse model. This correlation provides an efficient alternative method to measure, three-dimensionally, the total and regional dose absorbed from 18F-radiotracers.ConclusionsThe Fricke dosimeter can be used to calibrate a PET scanner, thus enabling the determination of dose from the measured radioactivity emitted by 18F-FDG in tissues. The method should be applicable to radiotracers with other positron-emitting radionuclides.

show abstract

Section: Discussionmentioning

confidence: 99%

Estimation of the Internal Dose Imparted by 18F-Fluorodeoxyglucose to Tissues by Using Fricke Dosimetry in a Phantom and Positron Emission Tomography

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The interpolation function was used to estimate initial %ID/organ and the time-integrated activity concentration (TIAC). Absorbed dose per injected activity for various organs was calculated with the TIAC factors and S-values for a standard man from the OpenDose project [ 21 ]. Effective dose was evaluated according to the ICRP 103 recommendations.…”

Section: Methodsmentioning

confidence: 99%

Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates

et al. 2020

View full text Add to dashboard Cite

Recently, radiolabelled antagonists targeting somatostatin receptors subtype 2 (SST2) in neuroendocrine neoplasms demonstrated certain superior properties over agonists. Within the ERA-PerMED project “TECANT” two 99mTc-Tetramine (N4)-derivatized SST2 antagonists (TECANT-1 and TECANT-2) were studied for the selection of the best candidate for clinical translation. Receptor-affinity, internalization and dissociation studies were performed in human embryonic kidney-293 (HEK293) cells transfected with the human SST2 (HEK-SST2). Log D, protein binding and stability in human serum were assessed. Biodistribution and SPECT/CT studies were carried out in nude mice bearing HEK-SST2 xenografts, together with dosimetric estimations from mouse-to-man. [99mTc]Tc-TECANT-1 showed higher hydrophilicity and lower protein binding than [99mTc]-TECANT-2, while stability was comparable. Both radiotracers revealed similar binding affinity, while [99mTc]Tc-TECANT-1 had higher cellular uptake (>50%, at 2 h/37 °C) and lower dissociation rate (<30%, at 2 h/37 °C). In vivo, [99mTc]Tc-TECANT-1 showed lower blood values, kidney and muscles uptake, whereas tumour uptake was comparable to [99mTc]Tc-TECANT-2. SPECT/CT imaging confirmed the biodistribution results, providing the best tumour-to-background image contrast for [99mTc]Tc-TECANT-1 at 4 h post-injection (p.i.). The estimated radiation dose amounted to approximately 6 µSv/MBq for both radiotracers. This preclinical study provided the basis of selection of [99mTc]Tc-TECANT-1 for clinical translation of the first 99mTc-based SST2 antagonist.

show abstract

“…A new free software at the organ level is being developed by the OPENDOSE collaboration [104], meant for diagnostic applications and radiation protection and presently under validation. As a novelty, it allows the user to choose among different radiation spectra, different phantoms (with associated radiation protection parameters) and different SAF values, including those provided by OPENDOSE itself with uncertainty estimates [105].…”

Section: Organ Level or Phantom-based Software Packagesmentioning

confidence: 99%

Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects

Danieli

Milano

Gallo

et al. 2022

JPM

Self Cite

View full text Add to dashboard Cite

Targeted radiation therapy (TRT) is a strategy increasingly adopted for the treatment of different types of cancer. The urge for optimization, as stated by the European Council Directive (2013/59/EURATOM), requires the implementation of a personalized dosimetric approach, similar to what already happens in external beam radiation therapy (EBRT). The purpose of this paper is to provide a thorough introduction to the field of personalized dosimetry in TRT, explaining its rationale in the context of optimization and describing the currently available methodologies. After listing the main therapies currently employed, the clinical workflow for the absorbed dose calculation is described, based on works of the most experienced authors in the literature and recent guidelines. Moreover, the widespread software packages for internal dosimetry are presented and critical aspects discussed. Overall, a selection of the most important and recent articles about this topic is provided.

show abstract

OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry

Cited by 60 publications

References 19 publications

Estimation of the Internal Dose Imparted by 18F-Fluorodeoxyglucose to Tissues by Using Fricke Dosimetry in a Phantom and Positron Emission Tomography

Estimation of the Internal Dose Imparted by 18F-Fluorodeoxyglucose to Tissues by Using Fricke Dosimetry in a Phantom and Positron Emission Tomography

Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates

Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects

Contact Info

Product

Resources

About